期刊文献+

抗高血压药物阿利克仑的合成研究

Study on the synthesis of antihypertensive drug aliskiren
原文传递
导出
摘要 目的研究抗高血压药阿利克仑的化学合成方法。方法以光学纯中间体(3S5,S,1'S3,'S)-5-(1'-叠氮基-3'-羟甲基-4'-甲基戊基)-3-异丙基二氢呋喃-2-酮为起始原料,经氧化、亲核加成、氢化、Boc保护、氨解、脱保护等反应得到阿利克仑游离碱。结果与结论以总收率35.7%合成阿利克仑。该合成路线反应步骤少,操作简便,收率高,反应条件温和,适合工业化生产。 Aliskiren was an orally active non-peptide renin inhibitors in renin angiotensin aldosterone system(RAS).It was the first one with new pharmacological mechanism in the field of hypertension treatment.The synthesis of aliskiren has been accomplished through 5 steps from(3S,5S,1′S,3′S)-5-(1′-azido-3′-hydroxymethyl-4′-methylpentyl)-3-isopropyl-dihydrofuran-2-one,which was efficiently transformed into 3(S)-isopropyl-5(S)-[1(S)-azido-3(S)-isopropyl-4-oxobutyl]-tetrahydrofuran-2-one(2) by NaClO/TEMPO catalyzed oxidation.Nucleophilic addition of aldehyde 2 with 4-methoxy-3-(3-methoxy-propyloxy)-bromobenzene afforded the desired unseparable diastereomers product 3 with the treatment of n-BuLi at-78 ℃ in 70% yield.Compound 3 was then allowed to hydrogenolysis and amino protection to provide the key intermediate lactone 4,which was followed by aminolysis and deprotection.The target compound aliskiren was achieved in 35.7% overall yield.In this improved process,the aldehyde 2 was easily prepared by oxidation of the corresponding alcohol catalyzed by NaClO-TEMPO in 92% yield.While it was obtained from the corresponding acid chloride by DIBAL-H reduction with very low temperature and strict reaction conditions,and low yield.The structure of the intermediates and the target compound were confirmed by 1H-NMR and IR analysis and are in good agreement with those reported.The developed method has some advantages such as simple starting materials,mild reaction conditions,ease operations and high yield.
出处 《中国药物化学杂志》 CAS CSCD 2011年第5期386-390,共5页 Chinese Journal of Medicinal Chemistry
基金 浙江省自然科学基金项目(Y4100692)
关键词 光学纯中间体 阿利克仑 抗高血压药 化学合成 enantiopure intermediate aliskiren antihypertensive drug chemical synthesis
  • 相关文献

参考文献7

  • 1SIRAGY H M, KAR S, KIRKPATRICK P. Aliskiren [J]. Nat Rev Drug Discov,2007,6 (10) :779 - 780.
  • 2JENSEN C, HEROLD P, BRUNNER H R. Aliskiren: the first renin inhibitor for clinical treamnet [ J ]. Nat Rev Drug Discov, 2008,7 ( 5 ) : 399 - 410.
  • 3GOSCHKE R,MAIBAUM J K, SCHILLING W,et al. δ-Amino-γ-hydroxy-to-aryl-alkanoic acid amides: US, 5559111[ P]. 1996 -09 -24.
  • 4SEDELMEIER G, GRIMLER D, ACEMOGLU M. Organic compounds: WO, 2007045420 [P]. 2007 - 04 - 26.
  • 5KIDEMET D, ZUPET R. Process and intermediates for the preparation of aliskiren: EP, 2062874 [P]. 2009 - 05 - 27.
  • 6MAIBAUM J, STUTZ S, GOSCHKE R, et al. Structural modification of the p2' position of 2,7-dialkyl-substituted 5 ( S ) -amino-4 ( S ) -hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent non- peptide human renin inhibitor active after once daily dosing in marmosets [ J ]. J Med Chem, 2007, 50 (20) :4832 - 4844.
  • 7HANESSIAN S,GUESNE S, CHENARD E. Total synthesis of "aliskiren" : the first renin inhibitor in clinical practice for hypertension[ J]. Org Lett,2010, 12(8) :1816 - 1819.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部